No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
Protalix BioTherapeutics Earnings Call: Growth Amid Challenges
Protalix BioTherapeutics Targets Phase 2 Launch for PRX-115 in H2 2025
Small Cap Wrap: Protalix Biotherapeutics, Delivra Health, HIVE Digital, U.S. Global Investors...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Protalix Biotherapeutics | 10-Q: Q1 2025 Earnings Report